查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922954

全磁浮左心室辅助装置市场：按电源、患者年龄、应用、最终用户和通路－2026-2032年全球预测

Fully MagLev Left Ventricular Assist Device Market by Power Source, Patient Age, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全磁浮左心室辅助装置市场预计到 2025 年价值 15.9 亿美元，到 2026 年将成长到 17.8 亿美元，到 2032 年达到 32.7 亿美元，复合年增长率为 10.83%。

关键市场统计数据
基准年 2025 15.9亿美元
预计年份：2026年 17.8亿美元
预测年份 2032 32.7亿美元
复合年增长率 (%) 10.83%

权威的介绍概述了全磁浮左心室辅助装置的临床和技术进步及其对医疗保健服务的影响。

全磁浮左心室辅助装置的出现标誌着晚期心臟衰竭治疗领域的一个重要转折点，它将机械工程的精准性与临床上对耐用性和血液相容性的迫切需求完美结合。这些新一代帮浦最大限度地减少了机械接触，降低了血液剪切应力，从而降低了装置相关溶血、血栓症和神经系统不利事件的发生率。临床医生正日益重视这些系统，不仅将其视为一种过渡治疗策略，而且将其视为在无法立即进行心臟移植时的持久替代方案。

说明了正在重塑磁浮左心室辅助装置（LVAD）治疗的采用、采购和长期管理的融合技术、监管和临床变革。

由于技术、监管和临床实践的动态发展，全磁浮左心室辅助装置（LVAD）的模式正在迅速变化。在技​​术层面，先进磁浮技术、改良的血液相容性表面以及嵌入式诊断功能的整合，正在提升LVAD的治疗效果，从而延长其功能寿命并降低併发症率。在临床层面，随着心臟团队在移植过渡治疗和根治性治疗中对这些系统的使用信心不断增强，患者选择标准也在不断演变，扩大了适用患者群体，并重新定义了长期照护路径。

对2025年美国关税变化将给全磁浮装置（LVAD）的开发商和供应商带来的供应链、采购和供应方面的复杂性进行深入分析

美国关税及贸易政策调整（至2025年）正为医疗设备采购、零件供应和跨境分销策略带来新的变数。依赖全球供应链采购精密磁铁、电力电子元件和特殊聚合物的製造商正面临到岸成本波动加剧的局面，这影响着零件供应、库存缓衝和製造地的决策。这些趋势促使医疗器材开发商重新评估供应商多元化和近岸外包方案，以满足专案进度和品质标准。

基于细分市场的详细洞察，解释了应用、分销模式、患者人口统计特征、电源架构和最终用户画像如何决定采用路径和专案设计。

从成熟的临床和商业性观点分析全磁浮装置（LVAD）市场，可以发现各细分市场的发展趋势存在差异，呈现不同的应用路径和使用模式。根据应用领域，该市场可分为过渡性治疗、移植过渡和终末治疗。每种应用领域对设备生命週期预期、监测方案和临床结果的重点各不相同，其中辅助性治疗侧重于短期可靠性，而终末治疗侧则侧重于长期耐用性和患者生活品质。根据分销管道，该市场可分为直销和分销商销售。直销模式有利于密切的临床合作和术后支持，而经销商通路则有助于扩大地域覆盖范围和建立本地服务网络。

全面的区域分析揭示了医疗保健基础设施、报销制度和临床能力方面的差异将如何影响世界各地采用磁浮左心室辅助装置 (LVAD) 解决方案的情况。

区域差异将影响全磁浮（LVAD）解决方案的临床实践模式、监管参与和商业性部署。在美洲地区，某些司法管辖区的先进心臟病计画和整合的支付系统正在推动早期临床应用和长期疗效数据的积累，使卓越中心能够不断改进术后护理模式。相较之下，在欧洲、中东和非洲地区（EMEA），区域医疗保健系统结构导致报销途径各异，因此需要製定个人化的市场进入策略，充分考虑各国的卫生技术评估（HTA）流程、医院采购惯例和区域医疗中心的能力。

从公司层面深入洞察技术领先地位、策略伙伴关係关係和强大的售后能力如何决定磁浮装置 (LVAD) 开发中的竞争优势

全磁浮装置（LVAD）领域的竞争格局以深厚的技术专长、战略伙伴关係以及对上市后证据产生的重点投入为特征。成熟的医疗设备製造商和专注于此领域的Start-Ups都在优先考虑对磁性技术、生物材料和整合诊断进行持续的研发投入，以确保设备的长期可靠性和临床医生的信心。同时，各公司正在加强与学术机构、契约製造和数位医疗服务提供者的合作，以加速证据产生并将远端监测整合到标准治疗方案中。

针对经营团队和临床领导者的具体建议：协调证据、增强供应链韧性、整合服务模式，以加速安全推广并创造长期价值。

产业领导者必须将临床证据的生成与稳健的营运实务结合，才能将技术潜力转化为持续的病患获益和商业性可行性。製造商应优先收集植入登记和核准后监测中嵌入的纵向安全性和生活品质数据，以确保真实世界证据能够支撑与支付方的对话和增强临床医生的信心。同时，策略性供应链多元化，包括检验的二级供应商和区域生产方案，可以降低贸易政策变化和零件集中度带来的风险。

我们采用透明、以临床医生为导向的调查方法，结合专家访谈、监管审查和同行检验证据，以产生可操作的医疗设备和专案见解。

本分析的调查方法融合了定性专家对话、系统性临床文献综述、监管申报文件以及医疗设备性能数据集，旨在构建一个平衡且以实践为导向的观点。主要研究内容包括与临床医生、外科专案主任、供应链经理和医疗设备工程师进行结构化访谈，以揭示现实世界中的限制因素、患者选择方面的细微差别以及医疗设备生命週期管理方面的考虑。这些第一手见解辅以对同行评审的临床研究、监管摘要和技术白皮书的反覆审查，以确保技术论点基于检验的证据。

总之，我们的综合分析强调了证据、运作韧性和临床医生支持如何共同决定磁浮左心室辅助装置 (LVAD) 的永续采用及其对患者的影响。

全磁浮左心室辅助装置融合了技术创新与临床需求，可望提高血液相容性、减少机械故障模式并改善患者体验。其成功应用不仅取决于装置效能，也取决于临床计画的准备情况，包括先进的监测、看护者培训和长期追踪。随着生态系统的日趋成熟，成功将取决于严谨的真实世界证据、稳健的供应链以及能够降低安全应用障碍的商业性永续服务模式的整合。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 全磁浮左心室辅助装置市场（依电源划分）

  • 外接电池
  • 商用电源

9. 依患者年龄分類的全磁浮左心室辅助装置市场

  • 成人版
  • 儿童

第十章 全磁浮左心室辅助装置市场（依应用划分）

  • 通往復健的桥樑
  • 移植桥樑
  • 最终治疗

第十一章 全磁浮左心室辅助装置市场（依最终用户划分）

  • 心臟中心
  • 医院

第十二章 全磁浮左心室辅助装置市场（依分销管道划分）

  • 直销
  • 透过分销商销售

第十三章 各地区全磁浮左心室辅助装置市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 全磁浮左心室辅助装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国全磁浮左心室辅助装置市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 美国全磁浮左心室辅助装置市场

第十七章 中国全磁浮左心室辅助装置市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • CH Biomedical Co., Ltd.
  • CorWave SA
  • Evaheart Inc.
  • Jarvik Heart Inc.
  • Leviticus Cardio LLC
  • Medtronic plc
  • ReliantHeart Inc.
  • Shenzhen Core Medical Technology Co., Ltd.
  • Suzhou Tongxin Medical Devices Co., Ltd.
  • SynCardia Systems LLC
  • Teleflex Incorporated
Product Code: MRR-867BED9A9E7F

The Fully MagLev Left Ventricular Assist Device Market was valued at USD 1.59 billion in 2025 and is projected to grow to USD 1.78 billion in 2026, with a CAGR of 10.83%, reaching USD 3.27 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.59 billion
Estimated Year [2026] USD 1.78 billion
Forecast Year [2032] USD 3.27 billion
CAGR (%) 10.83%

An authoritative introduction framing the clinical and engineering advances that define fully maglev left ventricular assist devices and their implications for care delivery

The advent of fully magnetically levitated left ventricular assist devices represents a pivotal inflection point in advanced heart failure therapy, merging mechanical engineering precision with clinical imperatives for durability and hemocompatibility. These next-generation pumps minimize mechanical contact, reducing shear stress on blood and lowering the incidence of device-related hemolysis, thrombosis, and adverse neurologic events. Clinicians are increasingly evaluating these systems not only for bridging strategies but also as durable alternatives where transplantation is not immediately feasible.

In parallel, improvements in biocompatible materials, computational fluid dynamics, and sensor-driven controls have improved device responsiveness and safety, enabling more refined patient management pathways. As a result, multidisciplinary teams including cardiac surgeons, heart failure cardiologists, perfusionists, and device engineers are collaborating earlier in the treatment continuum. Consequently, procurement, clinical adoption, and long-term care models must adapt to the operational realities of fully maglev technology, including new requirements for monitoring, power management, and post-market surveillance

A clear exposition of the convergent technological, regulatory, and clinical shifts reshaping adoption, procurement, and long-term management of maglev LVAD therapies

The landscape around fully maglev left ventricular assist devices is shifting rapidly as a result of converging forces in technology, regulation, and clinical practice. Technologically, the integration of advanced magnetic suspension, improved hemocompatible surfaces, and embedded diagnostics has elevated the therapeutic profile of LVADs, enabling longer functional life and lower complication rates. Clinically, patient selection criteria are evolving as heart teams gain confidence in using these systems for both bridge-to-transplant and destination therapy scenarios, thereby expanding candidate pools and redefining long-term care pathways.

Regulatory and reimbursement ecosystems are also in motion; payers and health technology assessors are placing greater emphasis on real-world evidence and quality-of-life outcomes, prompting manufacturers to collect and disclose longitudinal performance metrics. Moreover, supply chain resilience and strategic manufacturing localization are emerging as determinants of program stability. Taken together, these transformative shifts are compelling stakeholders to reassess clinical protocols, investment strategies, and partnership models to capture the full potential of maglev LVADs

An incisive analysis of how 2025 United States tariff changes introduce supply chain, sourcing, and procurement complexity for fully maglev LVAD developers and providers

Recent tariff actions and trade policy adjustments in the United States for 2025 have introduced new variables into device sourcing, component procurement, and cross-border distribution strategies. Manufacturers that rely on globalized supply chains for precision magnets, power electronics, and specialized polymers face increased landed cost variability, which in turn influences decisions on component sourcing, inventory buffers, and manufacturing footprints. These dynamics are prompting device developers to reassess supplier diversification and nearshoring options to protect program timelines and quality standards.

Clinicians and hospital systems are correspondingly adapting purchasing strategies to mitigate procurement risk, emphasizing longer lead-time planning and closer collaboration with vendors on contractual protections. Meanwhile, investors and strategic partners are recalibrating capital allocation for clinical trials and production scale-up to reflect the evolving cost structure. Ultimately, the cumulative impact of tariff changes is less about a single cost figure and more about the strategic realignment they drive across manufacturing, supply security, and clinical deployment pathways

A detailed segmentation-driven insight that explains how application, distribution, patient demographics, power architecture, and end-user profiles determine adoption pathways and program design

Segment-specific dynamics reveal differentiated pathways to adoption and usage patterns across the fully maglev LVAD landscape when examined through established clinical and commercial lenses. Based on Application, market is studied across Bridge To Recovery, Bridge To Transplant, and Destination Therapy; each application imposes distinct device lifecycle expectations, monitoring regimens, and clinical outcome priorities, with bridge scenarios emphasizing short-term reliability and destination therapy emphasizing long-term durability and patient quality of life. Based on Distribution Channel, market is studied across Direct Sales and Distributor Sales; direct sales models facilitate tighter clinical integration and post-implant support, whereas distributor channels extend geographic reach and local service coverage.

Further nuance emerges when considering age demographics and power architectures. Based on Patient Age, market is studied across Adult and Pediatric; pediatric adoption remains constrained by anatomical and growth considerations, driving design adaptations and specialized surgical protocols. Based on Power Source, market is studied across External Battery and Mains Power; energy management strategies, battery life, and charging protocols materially affect outpatient mobility, homecare logistics, and caregiver training. Finally, based on End User, market is studied across Cardiac Centers and Hospitals; high-volume cardiac centers often act as early adopters with integrated heart failure programs, while general hospitals may require bundled support services to safely manage outpatient follow-up and emergency contingencies. Collectively, these segmentation lenses clarify investment priorities, clinical training needs, and commercialization pathways for stakeholders

Comprehensive regional insights that reveal how varying healthcare architectures, reimbursement frameworks, and clinical capabilities shape adoption of maglev LVAD solutions across global territories

Geographic variation shapes clinical practice patterns, regulatory interactions, and commercial deployment for fully maglev LVAD solutions. In the Americas, advanced cardiac programs and consolidated payer systems in certain jurisdictions favor early clinical adoption and the aggregation of long-term outcome data, enabling centers of excellence to iterate on post-implant care models. In contrast, different health system architectures across the Europe, Middle East & Africa region create heterogenous reimbursement pathways, requiring tailored market access strategies that account for national HTA processes, hospital procurement practices, and regional center capabilities.

Across the Asia-Pacific corridor, rising incidence of advanced heart failure, expanding tertiary care capacity, and active local manufacturing initiatives are driving a distinctive adoption trajectory. Patient demographics, surgical training pipelines, and the pace of regulatory harmonization vary significantly between high-income metropolitan centers and emerging regional hubs. Consequently, successful regional strategies blend clinical education, local partnership models, and adaptive pricing and service frameworks to address divergent stakeholder expectations while ensuring safe, high-quality program rollouts

Key company-level insights into how technological leadership, strategic partnerships, and robust post-market capabilities determine competitive advantage in maglev LVAD development

Competitive dynamics in the fully maglev LVAD arena are characterized by deep technology specialization, strategic partnerships, and a premium on post-market evidence generation. Established medical device firms and specialist startups alike prioritize sustained R&D investments in magnetics, biomaterials, and embedded diagnostics to secure long-term device reliability and clinician trust. In parallel, companies are forging collaborations with academic centers, contract manufacturers, and digital health providers to accelerate evidence generation and to integrate remote monitoring into standard care pathways.

Operational capabilities such as manufacturing quality systems, scalability, and regulatory affairs expertise remain decisive differentiators, while aftermarket services including training, warranty support, and outcome tracking underpin commercial success. As a result, organizations that can align clinical validation programs with robust supply chain strategies and clinician-facing service models are most likely to advance adoption. Strategic M&A and selective licensing of core technologies are further mechanisms by which players aim to consolidate capabilities and expand clinical indications over time

Actionable recommendations for executives and clinical leaders to synchronize evidence, supply resilience, and integrated service models that accelerate safe adoption and long-term value

Industry leaders must align clinical evidence generation with resilient operational practices to translate engineering promise into sustained patient benefit and commercial viability. Manufacturers should prioritize longitudinal safety and quality-of-life data collection embedded within implant registries and post-approval studies, ensuring that real-world evidence supports payer dialogues and clinician confidence. At the same time, strategic supply chain diversification, including validated secondary suppliers and localized production options, will mitigate the risk introduced by shifting trade policies and component concentration.

From a commercial perspective, tailored go-to-market strategies that differentiate between high-volume cardiac centers and broader hospital networks will enhance adoption. Investments in clinician education, integrated service bundles, and remote monitoring infrastructure will lower implementation friction and improve patient outcomes. Finally, cross-sector collaborations-spanning academic centers, digital health vendors, and specialty service providers-can accelerate the development of comprehensive care pathways that realize the full clinical and economic value of fully maglev LVAD therapy

A transparent, clinician-oriented research methodology combining expert interviews, regulatory review, and evidence cross-validation to produce actionable device and program insights

The research methodology underpinning this analysis blends qualitative expert engagement with systematic review of clinical literature, regulatory filings, and device performance datasets to generate a balanced, practice-oriented perspective. Primary inputs include structured interviews with clinicians, surgical program directors, supply chain managers, and device engineers, which illuminate real-world operational constraints, patient selection nuances, and device lifecycle management considerations. These firsthand insights are corroborated by an iterative review of peer-reviewed clinical studies, regulatory summaries, and technical white papers to ensure technical assertions are grounded in verifiable evidence.

To ensure robust interpretation, cross-validation steps were employed where emerging themes from interviews were tested against independent clinical registries and device safety communications. Analytical emphasis was placed on device design characteristics, hemocompatibility profiles, post-implant management protocols, and health system readiness. Throughout, care was taken to transparently document assumptions and to prioritize clinical relevance over speculative projections, enabling decision-makers to apply findings directly to program planning and vendor evaluation

A conclusive synthesis underscoring how evidence, operational resilience, and clinician support jointly determine the sustainable adoption and patient impact of maglev LVADs

Fully maglev left ventricular assist devices stand at the intersection of engineering innovation and clinical need, offering a pathway to improved hemocompatibility, fewer mechanical failure modes, and enhanced patient experiences. Adoption will be shaped not only by device performance but equally by the readiness of clinical programs to implement advanced monitoring, caregiver training, and long-term follow-up infrastructures. As the ecosystem matures, success will hinge on the integration of rigorous real-world evidence, resilient supply chains, and commercially viable service models that lower barriers to safe implementation.

Looking ahead, stakeholders that proactively align clinical validation with scalable manufacturing and tailored market access strategies will be best positioned to convert technological promise into sustainable clinical programs. By focusing on evidence, operational resilience, and clinician support, the community can accelerate adoption in a way that prioritizes patient outcomes while addressing the practical complexities of device deployment and continuity of care

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fully MagLev Left Ventricular Assist Device Market, by Power Source

  • 8.1. External Battery
  • 8.2. Mains Power

9. Fully MagLev Left Ventricular Assist Device Market, by Patient Age

  • 9.1. Adult
  • 9.2. Pediatric

10. Fully MagLev Left Ventricular Assist Device Market, by Application

  • 10.1. Bridge To Recovery
  • 10.2. Bridge To Transplant
  • 10.3. Destination Therapy

11. Fully MagLev Left Ventricular Assist Device Market, by End User

  • 11.1. Cardiac Centers
  • 11.2. Hospitals

12. Fully MagLev Left Ventricular Assist Device Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributor Sales

13. Fully MagLev Left Ventricular Assist Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Fully MagLev Left Ventricular Assist Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fully MagLev Left Ventricular Assist Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Fully MagLev Left Ventricular Assist Device Market

17. China Fully MagLev Left Ventricular Assist Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Berlin Heart GmbH
  • 18.7. BiVACOR Inc.
  • 18.8. CH Biomedical Co., Ltd.
  • 18.9. CorWave SA
  • 18.10. Evaheart Inc.
  • 18.11. Jarvik Heart Inc.
  • 18.12. Leviticus Cardio LLC
  • 18.13. Medtronic plc
  • 18.14. ReliantHeart Inc.
  • 18.15. Shenzhen Core Medical Technology Co., Ltd.
  • 18.16. Suzhou Tongxin Medical Devices Co., Ltd.
  • 18.17. SynCardia Systems LLC
  • 18.18. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL BATTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL BATTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL BATTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY MAINS POWER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY MAINS POWER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY MAINS POWER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 99. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 116. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 117. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 122. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)